This article identifies three more Israeli companies that are expected to receive FDA approval for treatments in 2023. They are Gamida Cell (Omidubicel / NiCord – bone marrow transplants); Protalix (PRX-102 – Fabry disease); and BioLineRX (BL-8040 / Motixafortide – … Continue reading →

Israel’s BioLineRx (see here previously) has reported positive results in the Phase 3 trial of its Motixafortide treatment in combination with G-CSF for multiple myeloma. The treatment demonstrated improvement from five-fold to 14-fold compared to the control. https://en.globes.co.il/en/article-biolinerx-soars-on-positive-phase-3-blood-cancer-trial-results-1001347840 https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-positive-top-line-results-genesis-phase-3

The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX (see here). BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity. https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-receives-orphan-drug-designation-motixafortide-bl-8040

In the latest Phase 2a trial of the pancreatic cancer treatment from Israel’s BioLineRx (see here) three-quarters of the patients at disease stage 4 were able to get their disease under control. The trial combined BL-8040, KEYTRUDA (Pembrolizumab) and chemotherapy. … Continue reading →

FDA designation for solid tumor treatment. (TY Atid-EDI) I reported previously (28 Jan) that the AGI-134 solid tumor treatment from Israel’s BiolineRX showed promise. The U.S. FDA has just granted Biological Product Designation for the novel immunotherapy compound. Early trials … Continue reading →

Israel’s BioLineRx has announced encouraging initial results from its Phase 2a trials of its BL-8040 treatment on patients with metastatic pancreatic cancer. After only five days of treatment the treatment substantially increased the numbers of T-cells fighting the tumors. https://www.prnewswire.com/news-releases/biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-cancer-300583808.html

When Israel’s BioLineRx bought UK’s Agalimmune, it also acquired its AGI-134 treatment for solid tumors. BioLineRX has just demonstrated successful results of AGI-134 in two pre-clinical melanoma studies. https://www.prnewswire.com/news-releases/biolinerx-reports-data-at-asco-sitc-conference-showing-complete-tumor-regression-by-agi-134-in-pre-clinical-studies-670669553.html

Israel’s BiolineRx is buying UK’s Agalimmune,for $6 million. The private UK-based company has developed an innovative, anti-cancer immunotherapy platform. treatment that not only kills the tumor cells at the site of injection, but also brings about a durable, follow-on, anti-metastatic … Continue reading →

Israel’s BiolineRX in conjunction with Ben Gurion University, Hadassah Medical Center and Novartis has developed a novel treatment BL-1220 that can restore liver function in patients with liver disease and injury. http://www.biolinerx.com/default.asp?pageid=16&itemid=469